Abstract
Introduction
This analysis examines the historical and forecast performance for Allergan in
the Rx pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and
analysis tool provides continually updated quantitative and qualitative
information.
Key reasons to purchase this research
- Benchmark Allergan' s performance against key rivals in the prescription
pharmaceutical sector
- Assess how the key Botox franchise stands up to the global recession and
the arrival of further competitors
- Analyze the impact of Allergan' s acquisition of Esprit Pharma in 2007,
namely its movement into the urology therapy market
| 
View Cart
